SCHEMBL25035302

SCHEMBL25035302

O=C(Cn1c(C2CC2)cc(=O)n2nc(C3=CCOCC3)nc12)Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WRN Q14191 1/20 0.44
▸ ORAI1 Q96D31 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.37
▸ CRACR2A Q9BSW2 2/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ POLB P06746 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MAPT P10636 4/20 0.34
▸ TP53 P04637 2/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ RXFP1 Q9HBX9 1/20 0.34
▸ MCHR1 Q99705 1/20 0.34
▸ LMNA P02545 3/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ MTOR P42345 1/20 0.34
▸ GPBAR1 Q8TDU6 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31713883 0.87 WRN (0.49) WRNKDM4EMEN1KMT2APOLB
SCHEMBL25037184 0.86 WRN (0.45) WRNORAI1KDM4EMEN1KMT2A
SCHEMBL25035217 0.81 WRN (0.49) WRNKDM4EMEN1KMT2APOLB
SCHEMBL25037269 0.81 KDM4E (0.43) ORAI1KDM4ECRACR2AMEN1KMT2A
SCHEMBL25037228 0.80 WRN (0.45) WRNKDM4EMAPTMCHR1LMNA
SCHEMBL27381970 0.80 WRN (0.53) WRNKDM4EMEN1KMT2APOLB
SCHEMBL27381697 0.80 WRN (0.47) WRNKDM4EMAPTMCHR1LMNA
SCHEMBL31713788 0.79 WRN (0.55) WRNKDM4EMEN1KMT2AMAPT
SCHEMBL25036912 0.77 WRN (0.45) WRNMAPTPIK3CAMTOR
SCHEMBL25037211 0.77 WRN (0.52) WRNKDM4EMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619104-A1 BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS Novartis AG (CH) 2025-09-24 — — EP disclosed
US-20240360118-A1 Bicyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2024-10-31 — — US disclosed
WO-2024105553-A1 BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS NOVARTIS AG (CH) 2024-05-23 — — WO disclosed
EP-4347596-A1 TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN) Novartis AG (CH) 2024-04-10 — — EP disclosed
US-20230046859-A1 Bicyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2023-02-16 — — US disclosed
WO-2022249060-A1 TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN) NOVARTIS AG (CH) 2022-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360118-A1 Bicyclic Compounds and their Uses H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 WRN 1829/4885ORAI1 2210/4885KDM4E 1587/4885
US-20230046859-A1 Bicyclic Compounds and their Uses H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 WRN 1829/4885ORAI1 2210/4885KDM4E 1587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback